Summary of the Conference Call on the Pharmaceutical Industry Industry Overview - **Industry**: Pharmaceutical Industry - **Rating**: Leading - **2026 Outlook**: Value recovery, upward trend continues, selective layout amidst differentiation [1] Core Insights and Arguments - **Industry Trends**: - The industry is expected to maintain a relatively fast growth rate despite tightening drug regulations and increasing challenges in new drug development in the U.S. [2] - The integration trend within the industry is just beginning, with leading players in high-growth segments showing strong long-term certainty [2] - **Private Hospitals**: - High-quality private hospital targets are recommended as cost control pressures ease and outdated capacities are eliminated, allowing for a return to faster growth [3] - Recommended stocks include Gushengtang and Haijia Medical, which are expected to rebound in the short term and have clear long-term expansion paths [3] - **Valuation Summary**: - A detailed table of various pharmaceutical companies with their stock codes, ratings, target prices, closing prices, earnings per share (EPS), price-to-earnings ratios (P/E), and other financial metrics is provided [4] Important but Overlooked Content - **Market Performance**: - The MSCI China Pharmaceutical Index increased by 62.0% year-to-date, outperforming the MSCI China Index by 31.8 percentage points [10] - The pharmaceutical sector has officially entered a rebound phase, with significant performance differentiation among sub-sectors [10] - **Policy Environment**: - The policy environment is improving, with the government supporting innovative drug development and introducing commercial insurance funds to supplement the medical insurance directory [11] - The latest round of medical insurance negotiations has successfully included 127 drugs outside the directory, indicating a shift towards a more balanced pricing strategy [11] - **Innovation and R&D**: - The industry is witnessing a positive cycle of R&D breakthroughs and global licensing, with many companies entering a "R&D investment - clinical breakthrough - global licensing" cycle [11] - As of September 2025, Chinese pharmaceutical companies have completed 103 overseas transactions, exceeding 77% of the total transaction amount for 2024 [11] - **Financial Performance**: - The overall revenue of the A-share pharmaceutical sector showed a marginal recovery in Q3 2025, with a 0.7% year-on-year increase, indicating strong operational resilience [17] - The sector's earnings growth expectations are improving, with leading companies showing rapid recovery in performance [11][20] - **Investment Opportunities**: - The report emphasizes two main investment lines: focusing on innovative companies with strong differentiation and product export potential, and capitalizing on the recovery of valuation multiples and earnings growth [32][34] - Specific recommendations include companies like Sanofi Pharmaceutical, Deqi Pharmaceutical, and Baiji Shenzhou, which have rich catalysts and are still undervalued [35] - **AI in Healthcare**: - The application of AI in healthcare is highlighted as a new theme for industry innovation, with significant market expansion potential [33] - **Future Outlook**: - The pharmaceutical industry is expected to maintain a stable upward trend in 2026, with a focus on fundamental performance and valuation [30] - The introduction of the commercial insurance innovative drug directory and ongoing policy reforms are anticipated to further enhance market sentiment and fundamental expectations [37]

Investment Rating - The report maintains a positive outlook on the pharmaceutical industry, recommending a focus on innovative drugs and sectors with improving performance, such as medical devices and upstream segments [3][4]. Core Insights - The pharmaceutical sector experienced a decline of 1.0% this week, ranking 17th among 31 sub-industries. The overall valuation of the pharmaceutical sector stands at 29.2 times earnings, placing it 10th among the primary industries [2][4][7]. - Key events include Fosun Pharma granting exclusive global rights for its oral GLP-1 drug to Pfizer, with potential total payments reaching $2.085 billion. Additionally, Eli Lilly's GLP-1/GIP/GCGR agonist Retatrutide showed promising Phase III clinical data, achieving a weight loss of 28.7% over 68 weeks [3][14][17]. - The report highlights significant mergers and acquisitions, such as Sobi's acquisition of Arthrosi for $950 million upfront and $550 million in milestone payments, and Zhaoli Pharmaceutical's planned acquisition of a multi-trace element injection asset group for approximately RMB 356 million [3][15][22]. Market Performance - The pharmaceutical index decreased by 1.0% this week, while the Shanghai Composite Index fell by 0.3%. The overall performance of the pharmaceutical sector was ranked 17th among 31 sub-industries [2][4][6]. - The report details the performance of various sub-sectors, with notable declines in medical circulation (-4.2%), offline pharmacies (-4.3%), and blood products (-4.1%), while medical R&D outsourcing saw an increase of 3.7% [7][11]. Recent Key Events - The report discusses recent business developments, including the approval of Shanghai Pharma's new drug, and the change of control at Tailong Pharmaceutical, which will now be under Jiang Pharmaceutical Holdings [20][22]. - It also notes the IPO application of Shiyao Innovation, which was accepted with a market value of RMB 47.9 billion, focusing on health-related sectors and innovative drugs [23]. Company Valuation - The report provides a valuation table for key companies in the pharmaceutical sector, indicating projected earnings per share (EPS) and price-to-earnings (PE) ratios for 2025 to 2027. For instance, Mindray Medical is projected to have a PE of 23 in 2025, while Hengrui Medicine is expected to have a PE of 48 [29].

Investment Rating - The report maintains an "Overweight" rating for the innovative pharmaceutical and medical device industry chain [3][5][6]. Core Insights - The report emphasizes the continuous recommendation of innovative drugs and medical devices, highlighting the high growth potential in the innovative pharmaceutical sector. It maintains "Overweight" ratings for companies such as Heng Rui Medicine, Hansoh Pharmaceutical, and others, indicating a potential for value re-evaluation [3][5]. - The report notes that the National Medical Insurance Administration has officially announced the 2025 medical insurance drug catalog, which includes 114 new drugs, 50 of which are first-class innovative drugs. This adjustment is seen as a validation of the support for innovation in the healthcare sector [3][5]. - The A-share pharmaceutical sector underperformed the broader market in the second week of December 2025, with the SW Pharmaceutical Biotechnology index declining by 1.0% compared to a 0.3% drop in the Shanghai Composite Index [7][18]. Summary by Sections Section 1: Continuous Recommendation of Innovative Drugs and Medical Devices - The report highlights the sustained recommendation of innovative drugs and medical devices, with a focus on companies that are expected to see performance growth and value re-evaluation [5][6]. Section 2: A-share Pharmaceutical Sector Performance - In the second week of December 2025, the A-share pharmaceutical sector's performance was weaker than the overall market, ranking 16th among the primary industries [7][18]. Section 3: Hong Kong and US Market Performance - The report indicates that the Hong Kong pharmaceutical sector also underperformed, while the US pharmaceutical sector showed stronger performance compared to the broader market [18].

12月12日，成渝地区国家先进制造业集群"强链融圈"暨成渝地区产业合作园区高质量发展推进活动 在成都举行。记者从活动上获悉，川渝两地锚定共同打造世界级先进制造业集群目标，携手共育成渝地 区电子信息先进制造集群和成渝地区生物医药集群2个国家先进制造业集群，规模总量突破2.2万亿元。 活动上，发布了成渝地区国家先进制造业集群及产业合作园区投资机会、企业供需、服务能力"三 张清单"和成渝地区双城经济圈产业合作园区典型案例。投资机会清单涉及四川蒲江经济开发区、重庆 开州高新技术产业开发区等35个川渝产业园区；企业供需清单围绕六大优势产业，聚焦产业链强链延链 补链关键领域精准对接，深入梳理重点企业在技术攻关、原材料供应、市场拓展、人才引进等方面近 200条需求；服务能力清单全面梳理科研、产业、金融等方面提供的专业化服务能力与公共服务资源。 现场启动了四川省产业园区"青年实干家计划"专项活动，19个市（州）53个产业园区的198个岗位面向 省内外高校发布，吸引一批硕博士研究生到园区和企业一线实践锻炼。 在生物医药专场活动上，发布104个生物医药公共服务平台清单，5项跨区域合作项目落地。这份清 单包括41个中试平台、28个 ...

Group 1 - The core point of the announcement is that Sichuan Kelun Pharmaceutical Co., Ltd. plans to implement a share incentive plan for its subsidiary, Kelun Biotech, to attract and retain core talent and align interests among shareholders, the company, and key personnel [1][10]. Group 2 - The incentive plan will grant restricted share units, with a maximum of 3,500,000 H-shares to be issued, representing approximately 1.5% of the total shares of Kelun Biotech on the date of approval [2]. - The plan aims to establish a long-term incentive mechanism to support the strategic and operational goals of Kelun Biotech [3]. - The plan will be effective for ten years from the adoption date, with no new share awards to be granted after the expiration [3]. Group 3 - Eligible participants include directors and employees of Kelun Biotech and its subsidiaries, with selection based on performance, tenure, and contributions [4]. - The purchase price for the shares is set at RMB 1.00 per share, with a vesting period of four years, and performance targets must be met for the shares to vest [6]. - The management of the incentive plan will be overseen by the board of directors or authorized representatives of Kelun Biotech [7]. Group 4 - The incentive plan has been approved by the board of directors of Kelun Biotech but requires shareholder approval and listing approval from the Hong Kong Stock Exchange [9]. - The implementation of the plan is expected to enhance the core competitiveness and sustainable development of Kelun Biotech without adversely affecting the financial status or operational results of the parent company [10].

证券代码：002422 证券简称：科伦药业 公告编号：2025-085 四川科伦药业股份有限公司 关于控股子公司拟实施 2025 年股份激励计划的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误 导性陈述或重大遗漏。 为建立并完善长期激励机制，吸引并留住核心人才以推动控股子公司业务发 展及成功，有效协调股东、公司及核心人员的利益，促进共同关注长期发展，四 川科伦药业股份有限公司（以下简称"本公司"）控股子公司四川科伦博泰生物 医药股份有限公司（以下简称"科伦博泰"，股份代码：6990.HK）拟实施2025 年股份激励计划（以下简称"激励计划"）。 一、激励计划概述 激励计划授出的股份奖励为受限制股份单位形式，其对应的股份来源包括： （1）科伦博泰发行的新H股；（2）科伦博泰H股库存股（如有）；（3）科伦博 泰的受托人在公开市场购入的科伦博泰H股。 根据科伦博泰激励计划可授出的所有涉及发行新H股（包括使用库存股配发 及发行的股份）的股份奖励，所发行的最高股份数合计不超过3,500,000股H股， 预计占股东会审议通过激励计划当日科伦博泰股份总数（不包括库存股）的约 1.5%。不考 ...

Core Viewpoint - Kolun Pharmaceutical (002422.SZ) announced the implementation of a long-term incentive plan for its subsidiary, Sichuan Kolun Botai Biopharmaceutical Co., Ltd. (6990.HK), aimed at attracting and retaining key talent to drive business development and align interests among shareholders, the company, and core personnel [1] Group 1 - The incentive plan will grant restricted stock units, with shares sourced from new H-shares issued by Kolun Botai, existing treasury shares (if any), and shares purchased in the open market by a trustee [1] - The maximum number of shares to be granted under the incentive plan will not exceed 3,500,000 H-shares, which is approximately 1.5% of the total shares of Kolun Botai as of the date of the shareholders' meeting approving the plan [1] - The issuance of new H-shares under the plan will not significantly alter the company's ownership stake in Kolun Botai, which will remain a controlled subsidiary [1]

Core Viewpoint - The recent reform of the compensation system in the public fund industry has drawn significant market attention, marking the arrival of an "era of performance" where nearly a thousand fund managers face potential salary reductions due to underperformance [1][7]. Summary by Relevant Sections Compensation Reform - According to the new guidelines from the Asset Management Association of China, if a fund manager's product returns are more than 10 percentage points below the performance benchmark over the past three years and the fund's profit margin is negative, their performance-based compensation must be reduced by at least 30% [8]. - Fund companies are required to assess the performance of fund managers managing multiple products based on weighted criteria such as fund size and management duration, excluding funds managed for less than a year from evaluation [8]. Performance Data - As of December 10, there are 9,430 funds with performance data over the past three years, of which 1,615 funds have underperformed their benchmarks by more than 10 percentage points, and 56 funds have underperformed by over 50 percentage points [8]. - Notable underperforming funds include Guangfa High-end Manufacturing A, Fangzheng Fubon Innovation Power A, and Zheshang Smart Economic Dynamics A, with underperformance rates of 82.38%, 75.34%, and 69.84% respectively [8]. Focus on Fund Managers - The performance of senior fund managers over the past three years has become a focal point in the industry, particularly for Chen Xuanmiao from Penghua Fund, whose multiple products have shown poor performance [8]. - Data indicates that all five products managed by Chen Xuanmiao have negative returns compared to their benchmarks, with significant underperformance [8]. Specific Fund Performance - The Penghua Jiangxin Selected A fund has underperformed its benchmark by 28%, while Penghua Vision Return has underperformed by 24.53%, and other funds managed by Chen have similar negative returns [10]. - These funds have experienced notable net value declines, with maximum drawdowns ranging from 21% to 30% [10]. Portfolio Analysis - The top ten holdings across Chen Xuanmiao's five funds show a high degree of overlap, with a significant focus on consumer, pharmaceutical, and some undervalued cyclical sectors [10]. - Key stocks in the top holdings include Gree Electric Appliances, Kweichow Moutai, Renfu Pharmaceutical, and Mindray Medical, all of which are present in all five products [13]. Industry Transformation - The binding of fund managers' performance compensation to specific product benchmarks, rather than solely to fund size and management fees, indicates a profound restructuring of the asset management industry's operational rules [12]. - This shift signifies a fundamental change in industry values, emphasizing long-term investment philosophy, sustainable performance, and overall research capabilities of firms [12].

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry, indicating an expected return that is stronger than the market benchmark by over 5% [5]. Core Insights - The National Medical Insurance Administration is strongly encouraging the high-quality development of innovative drugs, with clear policies supporting the payment side for innovative drugs. Domestic leading innovative drug companies are entering a commercial realization phase [3][7]. - The 2025 National Medical Insurance Drug List includes 127 products, with 114 successfully added, of which 50 are innovative drugs, marking a historical high. The overall negotiation success rate reached 90%, the highest in nearly seven years [7]. - The report highlights that the domestic innovative drug market is becoming increasingly concentrated, with leading companies like Heng Rui and Xin Da Biotech significantly benefiting from the new insurance policies [7]. Summary by Sections Investment Recommendations and Targets - Recommended stocks include Heng Rui Pharmaceutical (600276, Buy), Ke Lun Pharmaceutical (002422, Buy), Xin Li Tai (002294, Hold), Ao Sai Kang (002755, Buy), Jing Xin Pharmaceutical (002020, Buy), and others [3]. Market Dynamics - The report notes that the introduction of the commercial insurance directory marks the beginning of a "new golden decade" for Chinese innovative drugs, with a focus on high clinical efficacy and value innovation [7]. - The report emphasizes that the competition in the GLP-1 market remains clear, with the entry of new drugs not significantly altering the competitive landscape for existing treatments [7].

Core Insights - The conference "2025 Financial Empowerment of the Medical and Health Industry (Guangxi) Innovation Conference" was successfully held in Nanning, focusing on building a closed-loop ecosystem of "technology innovation + capital empowerment + industry landing" to support Guangxi in becoming a healthcare industry hub facing ASEAN [2] - The "2025 China Innovative Drug Industry Investment Blue Book" was jointly released, providing authoritative and practical development trend analysis and investment layout guidance for industry participants, investors, and policymakers [2] Industry Development Background - The demand for innovative drugs is shifting from "curative" to "long-term management" and "precision" due to population aging and chronic diseases [6] - The number of rare diseases is increasing, necessitating the development of effective treatments [6] - AI-driven drug development is shortening research cycles, and innovative biopharmaceutical technologies are flourishing [6] Global Innovative Drug Development Trends - The number of innovative drugs in the oncology field is steadily increasing, with its share rising from 35% in 2020 to 45% in 2024, driven by breakthroughs in targeted therapies and CAR-T cell therapies [8] - From 2015 to 2024, a total of 12,263 innovative drugs are expected to be developed globally, with 9,427 still active by the end of 2024 [10] - China has become the country with the most innovative drugs since 2020, reaching 704 by 2024, surpassing the U.S. [11] China’s Innovative Drug Industry Development - The Chinese innovative drug industry has evolved through four stages: initial stage, combination of imitation and innovation, rise of innovation, and globalization [19] - The policy environment has increasingly focused on supporting innovative drugs, with a systematic policy matrix established to accelerate their transition from laboratory to clinical application [17] Market Size and Financing Trends - The innovative drug market in China is projected to reach CNY 1,620 billion by 2024, with commercial health insurance accounting for only 7.7% of the payment market [25] - The financing landscape has shifted from a focus on quantity to quality, with a notable increase in the proportion of domestic companies' innovative drugs approved in China, rising from under 10% in 2015 to 50% in 2024 [23] Future Opportunities and Challenges - The aging population and the demand for innovative drugs in oncology and chronic diseases are expected to continue growing [69] - The industry faces challenges such as geopolitical tensions, regulatory tightening, and high-risk characteristics of drug development, which typically takes over 10 years and requires substantial investment [71][72]